MedTrace Logo

An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris

NCT01466478 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-02-24

No results posted yet for this study

Summary

The purpose of the study is to compare the 3 ointment formulations containing LEO 29102 plus calcipotriol and Daivonex® ointment and Diprosone® ointment and to compare LEO 29102 plus calcipotriol to LEO 29102 alone and to calcipotriol alone in the same ointment vehicle, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment

once daily application, 4 weeks

DRUG

Ointment B: LEO 29102 2.5 mg/g ointment

once daily application, 4 weeks

DRUG

Ointment C: Calcipotriol 50 µg/g ointment

once daily application, 4 weeks

DRUG

Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment

once daily application, 4 weeks

DRUG

Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment

once daily application, 4 weeks

DRUG

Daivonex® ointment

once daily application, 4 weeks

DRUG

Diprosone® ointment

once daily application, 4 weeks

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Catherine Queille-Roussel, MD · Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD)

Study Design

Allocation
NA
Purpose
OTHER
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01466478 on ClinicalTrials.gov